These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 23090488)

  • 1. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
    Mattarollo SR; Steegh K; Li M; Duret H; Foong Ngiow S; Smyth MJ
    Immunol Cell Biol; 2013 Jan; 91(1):105-14. PubMed ID: 23090488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
    Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ
    Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
    Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
    Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
    Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
    Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
    Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
    Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
    Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
    Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DC therapy induces long-term NK reactivity to tumors via host DC.
    Shimizu K; Fujii S
    Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
    Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
    J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
    Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
    Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.
    Choi YS; Hoory T; Monie A; Wu A; Connolly D; Hung CF
    Vaccine; 2008 Oct; 26(46):5855-63. PubMed ID: 18771701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
    Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
    J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer T cell activation increases iNOS
    Paul S; Chhatar S; Mishra A; Lal G
    J Immunother Cancer; 2019 Aug; 7(1):208. PubMed ID: 31387637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconstitution models to evaluate natural killer T cell function in tumor control.
    Gebremeskel S; Slauenwhite D; Johnston B
    Immunol Cell Biol; 2016 Jan; 94(1):90-100. PubMed ID: 26095148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.
    Gonzalez-Aseguinolaza G; Van Kaer L; Bergmann CC; Wilson JM; Schmieg J; Kronenberg M; Nakayama T; Taniguchi M; Koezuka Y; Tsuji M
    J Exp Med; 2002 Mar; 195(5):617-24. PubMed ID: 11877484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide.
    Nakagawa R; Inui T; Nagafune I; Tazunoki Y; Motoki K; Yamauchi A; Hirashima M; Habu Y; Nakashima H; Seki S
    J Immunol; 2004 Jun; 172(11):6550-7. PubMed ID: 15153469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
    Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
    Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
    Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
    Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
    Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
    J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
    Nair RE; Kilinc MO; Jones SA; Egilmez NK
    J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.